Xencor | XNCR - Ebitda


Xencor reported $-34.63M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amgen USD 3.86B 1.28B Mar/2026
Arrowhead Research USD -147.68M 40.33M Jun/2026
AstraZeneca USD 5.16B 510M Jun/2026
Biogen USD 649.7M 76.5M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Cytokinetics USD -169.32M 19.48M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
J&J USD 8.27B 1.08B Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD -30.2M 52.15M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Pfizer USD 6.01B 18M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Xencor USD -34.63M 86.74M Jun/2026